Lin Elizabeth Yeu sold $127K of TARS (indirect holdings)

Lin Elizabeth Yeu (Chief Medical Officer) sold 1,590 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at $80.00 ($0.13M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lin Elizabeth Yeu
Published Sep 3, 2026, 8:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
high confidence
Mentioned
$TARS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

The sale is modest and pre‑arranged, suggesting no immediate market impact.

02

Market read

Routine insider sell with limited trading relevance.

03

What to watch

Potential upcoming clinical data could affect future insider activity.

Relevance 3/10Novelty 3/10Timing: post‑market 2026‑09‑02

Background

Form 4 filing reports insider transactions required by SEC; provides transparency.

Company-level read

Ticker impact

$TARSNeutralHigh confidence
Context

Chief Medical Officer Lin Elizabeth Yeu sold 1,590 shares for $127,200 via a 10b5‑1 plan.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is small relative to float and disclosed via pre‑arranged plan.

Market effects

None; isolated insider transaction.

None.

None.

Counterpoint

Even small insider sales can signal confidence issues, but no evidence here.

Key entities

  • Tarsus Pharmaceuticals, Inc.

    Biopharma developing therapies for rare diseases.

  • Lin Elizabeth Yeu

    Chief Medical Officer of Tarsus.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.